As the opioid epidemic continues, there is a mounting sense of urgency to improve access to high-quality early identification and treatment services. However, the need is outpacing capacity in many states and effective solutions to support primary care and specialty prescribers to identify and treat more patients with opioid use disorders are still emerging. This paper describes one state's approach to increase access to medication for opioid use disorders (MOUD) through development and implementation of a statewide addiction consultation service: Maryland Addiction Consultation Service (MACS).
Methods
Program components include a warmline, outreach and training, and resource and referral linkages for prescribers based on related consultation service models and documented barriers to prescribing MOUDs.
Results
Initial implementation outcomes indicate service components are being adopted as intended and by the target audience; many prescribers who engaged with the service have their buprenorphine waiver (44%) but do not have any additional formal addiction training (57%). Also, statewide penetration is promising with prescriber engagement in 100% of counites, however only 33% of counties in engaged in all four types of MACS services. Most calls (61%) originated from urban counties.
Conclusions
The MACS program increases access to specialty addiction medicine consultation and training through use of technology. MACS can serve as a model for other states looking to bridge the gap in access to addiction treatment.
HedegaardH, WarnerM, MiniñoAM.Drug overdose deaths in the United States, 1999–2015. NCHS data brief, no 273. Hyattsville, MD: National Center for Health Statistics; 2017.
WenLS, WarrenKE.Combatting the opioid epidemic: Baltimore's experience and lessons learned. J Public Heal (United Kingdom). 2018;40(2):e107–e111.
6.
SchwartzR, GryczynskiJ, O'GradyK, . Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–922.
7.
BartG.Maintenance medication for opiate addiction: The foundation of recovery. J Addict Dis. 2012;31(3):207–225.
8.
ConneryHS.Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.
9.
VolkowND, JonesEB, EinsteinEB, WargoEM.Prevention and treatment of opioid misuse and addiction: a Review. JAMA Psychiatry. 2019;76(2):208–216.
10.
JonesCM, McCance-KatzEF.Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78–82.
11.
KnudsenHK, AbrahamAJ, RomanPM.Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21–27.
12.
KnudsenHK, LofwallMR, WalshSL, HavensJR, StudtsJL.Physicians’ decision-making when implementing buprenorphine with new patients: conjoint analyses of data from a cohort of current prescribers. J Addict Med. 2018;12(1):31–39.
13.
BeethamT, SalonerB, WakemanSE, GayeM, BarnettML.Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study. Ann Intern Med. 2019;171(1):1.
14.
LagisettyPA, RossR, BohnertA, ClayM, MaustDT.Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019. 2019;76(9):979.
15.
LevinFR, BisagaA, SullivanMA, WilliamsAR, Cates-WesselK.A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. Am J Addict. 2016;25(8):603–609.
16.
Substance Abuse and Mental Health Services Administration. Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements. Final Rule; 2016.
KnudsenHK, AbrahamAJ, OserCB.Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. Eval Program Plann. 2011;34(4):375–381.
19.
HutchinsonE, CatlinM, AndrillaCHA, BaldwinLM, RosenblattRA.Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128–133.
20.
AndrillaCHA, CoulthardC, PattersonDG.Prescribing practices of rural physicians waivered to prescribe buprenorphine. Am J Prev Med. 2018;54(6 Suppl 3):S208–S214.
21.
TesemaL, MarshallJ, HathawayR, . Training in office-based opioid treatment with buprenorphine in US residency programs: a national survey of residency program directors. Subst Abus. 2018;39(4):434–440.
22.
SharfsteinJM, OlsenY.Making amends for the opioid epidemic. JAMA - J Am Med Assoc. 2019;321(15):1446.
23.
KnudsenHK.The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: a state-level analysis. J Stud Alcohol Drugs. 2015;76(4):644–654.
24.
Substance Abuse and Mental Health Services Administration. Medicaid coverage and financing of medications to treat alcohol and opioid use disorders. 2014. HHS Publication No. SMA-14-4854
25.
University of Maryland BSEC. Opioid treatment programs in Maryland needs assessment report; 2016. https://bha.health.maryland.gov/Documents/Combined OTP Needs Assessment Report and letter11.18.16.pdf.
26.
SarvetB, GoldJ, BosticJQ, . Improving access to mental health care for children: the Massachusetts Child Psychiatry Access Project. Pediatrics. 2010;126(6):1191–1200.
27.
SteinBD, KofnerA, VogtWB, YuH.A national examination of child psychiatric telephone consultation programs’ impact on children's mental health care utilization. J Am Acad Child Adolesc Psychiatry. 2019;58(10):1016–1019.
28.
GlothFM, SchwartzJ.Developing a physicians’ palliative care pain hotline in Maryland. Am J Hosp Palliat Care. 2000;17(1):24–28.
29.
Massachusetts Consultation Service for Treatment of Addiction and Pain. https://www.mcstap.com/. Published 2019.
GoldschmidtRH, GravesDW.The national HIV telephone consultation service (Warmline): a clinical resource for physicians caring for African-Americans. J Natl Med Assoc. 2003;95(2 SUPPL. 2):8S–11S.
34.
EganJE, CasadonteP, GartenmannT, . The physician clinical support system-buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010;25(9):936–941.
35.
CarrCH, McNealH, RegaladoE, NelesenRA, LloydLS.PAL-MED CONNECT®: a telephone consultation hotline for palliative medicine questions. J Palliat Med. 2013;16(3):263–267.
36.
HiltRJ, RomaireMA, McDonellMG, . The partnership access line: evaluating a child psychiatry consult program in Washington state. JAMA Pediatr. 2013;167(2):162–168.
37.
EatonJL, MohrDC, MohammadA, . Implementation of a novel occupational and environmental medicine specialty teleconsultation service: the VHA experience. J Occup Environ Med. 2015;57(2):173–177.
38.
HarrisonJ, WassermanK, SteinbergJ, PlattR, CobleK, BowerK.The five S's: a communication tool for child psychiatric access projects. Curr Probl Pediatr Adolesc Health Care. 2016;46(12):411–419.
39.
MarcusS, MalasN, DoppR, . The Michigan child collaborative care program: building a telepsychiatry consultation service. Psychiatr Serv. 2019;70(9):849–852.
GriggJ, ArunogiriS, ManningV, . The drug and alcohol clinical advisory service: a model of telephone-delivered addiction specialist support. Drug Alcohol Rev. 2020;39(3):238–245.
42.
AndrillaCHA, MooreTE, PattersonDG.Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Heal. 2019;35(1):113–121.
43.
JonesCM, McCance-KatzEF.Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019;114(3):471–482.
44.
PidanoAE, HonigfeldL, Bar-HalpernM, VivianJE.Pediatric primary care providers’ relationships with mental health care providers: survey results. Child Youth Care Forum. 2014;43(1):135–150.
45.
DeFlavioJR, RolinSA, NordstromBR, KazalLA.Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15(1):1–11.
46.
PearsonACS, EldrigeJS, MoeschlerSM, HootenWM.Opioids for chronic pain: a knowledge assessment of nonpain specialty providers. J Pain Res. 2016;9:129–135.
47.
KnickmanJ, KrishnanR, PincusH.Improving access to effective care for people with mental health and substance use disorders. JAMA - J Am Med Assoc. 2016;316(16):1647–1648.
48.
ConnorsEH, AroraP, BlizzardAM, . When behavioral health concerns present in pediatric primary care: factors influencing provider decision-making. J Behav Health Serv Res. 2018;45(3):340–355.
49.
HaffajeeRL, BohnertASB, LagisettyPA.Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230–S242.
PlattR, PustilnikS, ConnorsE, GloffN, BowerK.Severity of mental health concerns in pediatric primary care and the role of child psychiatry access programs. Gen Hosp Psychiatry. 2018;53:12–18.
53.
YoungA, ChaudhryHJ, PeiX, HalbeslebenK, PolkDH, DuganM.A census of actively licensed physicians in the United States, 2014. J Med Licens Discip. 2015;99(2), 11–24.
LagisettyPA, HealyN, GarpestadC, JannauschM, TipirneniR, BohnertASB.Access to primary care clinics for patients with chronic pain receiving opioids. JAMA Netw Open. 2019;2(7):e196928.
56.
BraithwaiteV, NolanS.Hospital-based addiction medicine healthcare providers. J Addict Med. 2019;13(4):251–252.
57.
GundersonEW, FiellinDA, LevinFR, SullivanLE, KleberHD.Evaluation of a combined online and in person training in the use of buprenorphine. Subst Abus. 2006;27(3):39–45.
58.
AroraPG, ConnorsEH, CobleK, BlizzardA, WissowL, PruittD.Pediatric primary care providers’ use of behavioral health consultation. Psychiatr Serv. 2017;68(6):531–534.
59.
DavisMT, BatemanB, AvornJ.Educational outreach to opioid prescribers: the case for academic detailing. Pain Phys. 2017;2(20):S147–S151.
60.
AndrillaCHA, JonesKC, PattersonDG.Prescribing practices of nurse practitioners and physician assistants waivered to prescribe buprenorphine and the barriers they experience prescribing buprenorphine. J Rural Heal. 2019;36(2):187–195.
MillerWR, SorensenJL, SelzerJA, BrighamGS.Disseminating evidence-based practices in substance abuse treatment: a review with suggestions. J Subst Abuse Treat. 2006;31(1):25–39.
63.
AroraS, ThorntonK, MurataG, . Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–2207.
64.
KomaromyM, DuhiggD, MetcalfA, . Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37(1):20–24.
